Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1α expression by blocking protein translation and increases cell death under hypoxia

References

• Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7:606 - 19; http://dx.doi.org/10.1038/nrg1879; PMID: 16847462
   PubMed Web of Science ®Google Scholar
• Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8:627 - 44; http://dx.doi.org/10.1038/nrd2926; PMID: 19644473
   PubMed Web of Science ®Google Scholar
• Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007; 408:297 - 315; http://dx.doi.org/10.1042/BJ20070797; PMID: 17850214
   PubMed Web of Science ®Google Scholar
• Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, Timms JF, et al. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J 2007; 404:15 - 21; http://dx.doi.org/10.1042/BJ20061489; PMID: 17302559
   PubMed Web of Science ®Google Scholar
• Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008; 7:1851 - 63; http://dx.doi.org/10.1158/1535-7163.MCT-08-0017; PMID: 18606717
   PubMed Web of Science ®Google Scholar
• Schnell CR, Stauffer F, Allegrini PR, O’Reilly T, McSheehy PM, Dartois C, et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res 2008; 68:6598 - 607; http://dx.doi.org/10.1158/0008-5472.CAN-08-1044; PMID: 18701483
   PubMed Web of Science ®Google Scholar
• Kaper F, Dornhoefer N, Giaccia AJ. Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. Cancer Res 2006; 66:1561 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-05-3375; PMID: 16452213
   PubMed Web of Science ®Google Scholar
• Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12:9 - 22; http://dx.doi.org/10.1016/j.ccr.2007.05.008; PMID: 17613433
   PubMed Web of Science ®Google Scholar
• Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110:163 - 75; http://dx.doi.org/10.1016/S0092-8674(02)00808-5; PMID: 12150925
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14:1296 - 302; http://dx.doi.org/10.1016/j.cub.2004.06.054; PMID: 15268862
   PubMed Web of Science ®Google Scholar
• Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene 2006; 25:6416 - 22; http://dx.doi.org/10.1038/sj.onc.1209888; PMID: 17041626
   PubMed Web of Science ®Google Scholar
• Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001; 15:807 - 26; http://dx.doi.org/10.1101/gad.887201; PMID: 11297505
   PubMed Web of Science ®Google Scholar
• Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000; 14:391 - 6; PMID: 10691731
   PubMed Web of Science ®Google Scholar
• Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 2001; 12:363 - 9; PMID: 11457733
   PubMedGoogle Scholar
• Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60:1541 - 5; PMID: 10749120
   PubMed Web of Science ®Google Scholar
• Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, et al. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 2010; 16:3628 - 38; http://dx.doi.org/10.1158/1078-0432.CCR-09-3022; PMID: 20606035
   PubMed Web of Science ®Google Scholar
• Pore N, Jiang Z, Shu HK, Bernhard E, Kao GD, Maity A. Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol Cancer Res 2006; 4:471 - 9; http://dx.doi.org/10.1158/1541-7786.MCR-05-0234; PMID: 16849522
   PubMed Web of Science ®Google Scholar
• Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721 - 32; http://dx.doi.org/10.1038/nrc1187; PMID: 13130303
   PubMed Web of Science ®Google Scholar
• Walsh D, Arias C, Perez C, Halladin D, Escandon M, Ueda T, et al. Eukaryotic translation initiation factor 4F architectural alterations accompany translation initiation factor redistribution in poxvirus-infected cells. Mol Cell Biol 2008; 28:2648 - 58; http://dx.doi.org/10.1128/MCB.01631-07; PMID: 18250159
   PubMed Web of Science ®Google Scholar
• Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M, Borden KL. eIF4E is a central node of an RNA regulon that governs cellular proliferation. J Cell Biol 2006; 175:415 - 26; http://dx.doi.org/10.1083/jcb.200607020; PMID: 17074885
   PubMed Web of Science ®Google Scholar
• Mamane Y, Petroulakis E, Martineau Y, Sato TA, Larsson O, Rajasekhar VK, et al. Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS One 2007; 2:e242; http://dx.doi.org/10.1371/journal.pone.0000242; PMID: 17311107
   PubMed Web of Science ®Google Scholar
• Moerke NJ, Aktas H, Chen H, Cantel S, Reibarkh MY, Fahmy A, et al. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 2007; 128:257 - 67; http://dx.doi.org/10.1016/j.cell.2006.11.046; PMID: 17254965
   PubMed Web of Science ®Google Scholar
• Gregory MA, Hann SR. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt’s lymphoma cells. Mol Cell Biol 2000; 20:2423 - 35; http://dx.doi.org/10.1128/MCB.20.7.2423-2435.2000; PMID: 10713166
   PubMed Web of Science ®Google Scholar
• Kanamoto R, Kameji T, Iwashita S, Igarashi K, Hayashi S. Spermidine-induced destabilization of ornithine decarboxylase (ODC) is mediated by accumulation of antizyme in ODC-overproducing variant cells. J Biol Chem 1993; 268:9393 - 9; PMID: 8486633
   PubMed Web of Science ®Google Scholar
• Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, Nicolaides T, et al. Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal 2010; 3:ra81; http://dx.doi.org/10.1126/scisignal.2001017; PMID: 21062993
   PubMed Web of Science ®Google Scholar
• Eskelinen EL. Fine structure of the autophagosome. Methods Mol Biol 2008; 445:11 - 28; http://dx.doi.org/10.1007/978-1-59745-157-4_2; PMID: 18425441
   PubMedGoogle Scholar
• Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000; 19:5720 - 8; http://dx.doi.org/10.1093/emboj/19.21.5720; PMID: 11060023
   PubMed Web of Science ®Google Scholar
• Carew JS, Nawrocki ST, Cleveland JL. Modulating autophagy for therapeutic benefit. Autophagy 2007; 3:464 - 7; PMID: 17495516
   PubMed Web of Science ®Google Scholar
• Xu CX, Zhao L, Yue P, Fang G, Tao H, Owonikoko TK, et al. Augmentation of NVP-BEZ235’s anticancer activity against human lung cancer cells by blockage of autophagy. Cancer Biol Ther 2011; 12:549 - 55; http://dx.doi.org/10.4161/cbt.12.6.16397; PMID: 21738008
   PubMed Web of Science ®Google Scholar
• Frezza C, Zheng L, Tennant DA, Papkovsky DB, Hedley BA, Kalna G, et al. Metabolic profiling of hypoxic cells revealed a catabolic signature required for cell survival. PLoS One 2011; 6:e24411; http://dx.doi.org/10.1371/journal.pone.0024411; PMID: 21912692
   PubMed Web of Science ®Google Scholar
• Jaakkola PM, Pursiheimo JP. p62 degradation by autophagy: another way for cancer cells to survive under hypoxia. Autophagy 2009; 5:410 - 2; http://dx.doi.org/10.4161/auto.5.3.7823; PMID: 19197142
   PubMed Web of Science ®Google Scholar
• Mazure NM, Pouysségur J. Hypoxia-induced autophagy: cell death or cell survival?. Curr Opin Cell Biol 2010; 22:177 - 80; http://dx.doi.org/10.1016/j.ceb.2009.11.015; PMID: 20022734
   PubMed Web of Science ®Google Scholar
• Tracy K, Dibling BC, Spike BT, Knabb JR, Schumacker P, Macleod KF. BNIP3 is an RB/E2F target gene required for hypoxia-induced autophagy. Mol Cell Biol 2007; 27:6229 - 42; http://dx.doi.org/10.1128/MCB.02246-06; PMID: 17576813
   PubMed Web of Science ®Google Scholar
• Soliman GA, Acosta-Jaquez HA, Dunlop EA, Ekim B, Maj NE, Tee AR, et al. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem 2010; 285:7866 - 79; http://dx.doi.org/10.1074/jbc.M109.096222; PMID: 20022946
   PubMed Web of Science ®Google Scholar
• Copp J, Manning G, Hunter T. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res 2009; 69:1821 - 7; http://dx.doi.org/10.1158/0008-5472.CAN-08-3014; PMID: 19244117
   PubMed Web of Science ®Google Scholar
• Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 2008; 111:379 - 82; http://dx.doi.org/10.1182/blood-2007-03-080796; PMID: 17878402
   PubMed Web of Science ®Google Scholar
• Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005; 4:1533 - 40; http://dx.doi.org/10.1158/1535-7163.MCT-05-0068; PMID: 16227402
   PubMed Web of Science ®Google Scholar
• Young RM, Wang SJ, Gordan JD, Ji X, Liebhaber SA, Simon MC. Hypoxia-mediated selective mRNA translation by an internal ribosome entry site-independent mechanism. J Biol Chem 2008; 283:16309 - 19; http://dx.doi.org/10.1074/jbc.M710079200; PMID: 18430730
   PubMed Web of Science ®Google Scholar
• Stoneley M, Paulin FE, Le Quesne JP, Chappell SA, Willis AE. C-Myc 5′ untranslated region contains an internal ribosome entry segment. Oncogene 1998; 16:423 - 8; http://dx.doi.org/10.1038/sj.onc.1201763; PMID: 9467968
   PubMed Web of Science ®Google Scholar
• Johannes G, Sarnow P. Cap-independent polysomal association of natural mRNAs encoding c-myc, BiP, and eIF4G conferred by internal ribosome entry sites. RNA 1998; 4:1500 - 13; http://dx.doi.org/10.1017/S1355838298981080; PMID: 9848649
   PubMed Web of Science ®Google Scholar
• Braunstein S, Karpisheva K, Pola C, Goldberg J, Hochman T, Yee H, et al. A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell 2007; 28:501 - 12; http://dx.doi.org/10.1016/j.molcel.2007.10.019; PMID: 17996713
   PubMed Web of Science ®Google Scholar
• Lang KJ, Kappel A, Goodall GJ. Hypoxia-inducible factor-1alpha mRNA contains an internal ribosome entry site that allows efficient translation during normoxia and hypoxia. Mol Biol Cell 2002; 13:1792 - 801; http://dx.doi.org/10.1091/mbc.02-02-0017; PMID: 12006670
   PubMed Web of Science ®Google Scholar
• Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955; 9:539 - 49; http://dx.doi.org/10.1038/bjc.1955.55; PMID: 13304213
   PubMed Web of Science ®Google Scholar
• Evans SM, Koch CJ. Prognostic significance of tumor oxygenation in humans. Cancer Lett 2003; 195:1 - 16; http://dx.doi.org/10.1016/S0304-3835(03)00012-0; PMID: 12767506
   PubMed Web of Science ®Google Scholar
• Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 4:437 - 47; http://dx.doi.org/10.1038/nrc1367; PMID: 15170446
   PubMed Web of Science ®Google Scholar
• Zindy P, Bergé Y, Allal B, Filleron T, Pierredon S, Cammas A, et al. Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors. Cancer Res 2011; 71:4068 - 73; http://dx.doi.org/10.1158/0008-5472.CAN-11-0420; PMID: 21498638
   PubMed Web of Science ®Google Scholar
• Zaytseva YY, Valentino JD, Gulhati P, Evers BM. mTOR inhibitors in cancer therapy. Cancer Lett 2012; 319:1 - 7; http://dx.doi.org/10.1016/j.canlet.2012.01.005; PMID: 22261336
   PubMed Web of Science ®Google Scholar
• Posadas EM, Figlin RA. Systemic therapy in renal cell carcinoma: advancing paradigms. [Williston Park] Oncology (Williston Park) 2012; 26:290 - 301; PMID: 22545314
   PubMed Web of Science ®Google Scholar
• Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int 2011; 108:1556 - 63; http://dx.doi.org/10.1111/j.1464-410X.2011.10629.x; PMID: 21952069
   PubMed Web of Science ®Google Scholar
• Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, Yoshimori T, et al. The role of autophagy during the early neonatal starvation period. Nature 2004; 432:1032 - 6; http://dx.doi.org/10.1038/nature03029; PMID: 15525940
   PubMed Web of Science ®Google Scholar
• Gupta AK, Li B, Cerniglia GJ, Ahmed MS, Hahn SM, Maity A. The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. Neoplasia 2007; 9:271 - 8; http://dx.doi.org/10.1593/neo.07124; PMID: 17460771
   PubMed Web of Science ®Google Scholar